Questcor Pharmaceuticals (QCOR) Slammed as Cerium Pharmaceuticals Granted FDA Orphan Drug Status
Tweet
Share
E-mailGet Alerts QCOR Hot Sheet
Join SI Premium – FREE
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) is under heavy pressure early Friday which is related to reports Cerium Pharmaceuticals received FDA orphan drug designation for Synacthen Depot, the synthetic equivalent of Acthar.
Shares of QCOR last traded at $23.79, down 6.5 percent.
Shares of QCOR last traded at $23.79, down 6.5 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU Antitrust Regulators Concerned About Impact of KKR, Telecom Italia Deal on Viability of Wholesale Market - Reuters
- Affirm Holdings (AFRM) on watch as Walmart (WMT) -backed fintech One introduces buy now, pay later
- Honda (HMC) to Build Electric Vehicles and Batteries in Ontario - Reuters
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
